Ahmet Murat Aydın
Assistant Professor
Also affiliated: Moffitt Cancer Center (2019–2025); Hacettepe University (2015–2020); The University of Texas Southwestern Medical Center (2017–2020)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Ahmet Murat Aydın is an Assistant Professor at the University of Arkansas for Medical Sciences whose research focuses on cancer biology and treatment outcomes. His work investigates the spatial distribution of immune cells within tumors, such as CD68+ tumor-associated macrophages and cancer-associated fibroblasts, and their correlation with patient survival in metastatic clear cell renal cell carcinoma. Aydın also studies tumor-infiltrating lymphocytes (TILs) in penile and bladder cancers, exploring factors that influence their expansion and potential therapeutic applications.
His research also examines the relationship between immune cell infiltration patterns and somatic mutations in advanced clear cell renal cell carcinoma. He has published on the concept of oncogenesis recapitulating embryogenesis and its implications for cancer care. Additionally, Aydın has contributed to studies on treatment protocols for muscle-invasive bladder cancer and the validation of artificial intelligence algorithms for prostate cancer detection using MRI.
Metrics
- h-index: 18
- Publications: 63
- Citations: 748
Positions
-
Assistant Professor 2021–presentUniversity of Arkansas for Medical Sciences Urology ORCID
Selected Publications
-
Testicular Plasmacytoma: A 25-Year Experience from a High-Volume Tertiary Center and Comparative Review of the Literature (2026)
-
Editorial Comment (2026)
-
Impact of intraoperative intravenous heparin bolus on clinical outcomes during radical nephrectomy and IVC tumor thrombectomy in renal cell carcinoma with level I–IV IVC thrombus: A multi-institutional study (2026)
-
A call for raising public awareness and improving outcomes of penile cancer (2025)
-
Response to the Letter on MRI in Prostate Cancer Screening and Clinical Trial Requirements (2025)
-
External Validation of an Artificial Intelligence Algorithm Using Biparametric MRI and Its Simulated Integration with Conventional PI-RADS for Prostate Cancer Detection (2025)
-
Minimally Invasive Management of Inguinal Lymph Nodes in Penile Cancer: Recent Progress and Remaining Challenges (2024)
-
Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer (2024)
-
Abstract A020: An early determination of patients eligibility for a bladder cancer immunotherapy using a data science approach (2024)
-
Identification of a panel of microRNA biomarkers for the management of patients with refractory germ cell tumor of the testis. (2024)
-
Giant left pheochromocytoma with vascular anomalies and pelvic horseshoe kidney: a case report (2023)
-
Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care (2023)
-
Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy (2023)
-
Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care (2023)
-
Abstract B015: Racial differences in epigenetic aging and its impact on expression of T-cell inhibitory receptors (2023)
Collaboration Network
Top Collaborators
- External Validation of an Artificial Intelligence Algorithm Using Biparametric MRI and Its Simulated Integration with Conventional PI-RADS for Prostate Cancer Detection
- Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care
- Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy
- Giant left pheochromocytoma with vascular anomalies and pelvic horseshoe kidney: a case report
- Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer
Showing 5 of 9 shared publications
- Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care
- Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer
- Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care
- Identification of a panel of microRNA biomarkers for the management of patients with refractory germ cell tumor of the testis.
- Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care
- Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy
- Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care
- Identification of a panel of microRNA biomarkers for the management of patients with refractory germ cell tumor of the testis.
- External Validation of an Artificial Intelligence Algorithm Using Biparametric MRI and Its Simulated Integration with Conventional PI-RADS for Prostate Cancer Detection
- Minimally Invasive Management of Inguinal Lymph Nodes in Penile Cancer: Recent Progress and Remaining Challenges
- Giant left pheochromocytoma with vascular anomalies and pelvic horseshoe kidney: a case report
- Impact of intraoperative intravenous heparin bolus on clinical outcomes during radical nephrectomy and IVC tumor thrombectomy in renal cell carcinoma with level I–IV IVC thrombus: A multi-institutional study
- Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
- Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy
- Abstract A020: An early determination of patients eligibility for a bladder cancer immunotherapy using a data science approach
- Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care
- Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy
- Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer
- Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care
- Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy
- Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer Care
- Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
- Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy
- Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
- Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy
- Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
- Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy
- Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
- Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy
- Minimally Invasive Management of Inguinal Lymph Nodes in Penile Cancer: Recent Progress and Remaining Challenges
- Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy
- Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
- Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy
- Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
- Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy
- Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
- Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy
Similar Researchers
Based on overlapping research topics